JP2011520903A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520903A5
JP2011520903A5 JP2011509679A JP2011509679A JP2011520903A5 JP 2011520903 A5 JP2011520903 A5 JP 2011520903A5 JP 2011509679 A JP2011509679 A JP 2011509679A JP 2011509679 A JP2011509679 A JP 2011509679A JP 2011520903 A5 JP2011520903 A5 JP 2011520903A5
Authority
JP
Japan
Prior art keywords
compound
salt
cyano
salt according
cyclopenta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509679A
Other languages
English (en)
Japanese (ja)
Other versions
JP5603327B2 (ja
JP2011520903A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/043875 external-priority patent/WO2009140448A1/en
Publication of JP2011520903A publication Critical patent/JP2011520903A/ja
Publication of JP2011520903A5 publication Critical patent/JP2011520903A5/ja
Application granted granted Critical
Publication of JP5603327B2 publication Critical patent/JP5603327B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509679A 2008-05-16 2009-05-14 テトラヒドロシクロペンタ[b]インドールアンドロゲン受容体調節物質 Active JP5603327B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5372208P 2008-05-16 2008-05-16
US61/053,722 2008-05-16
PCT/US2009/043875 WO2009140448A1 (en) 2008-05-16 2009-05-14 Tetrahydrocyclopenta[b]indole androgen receptor modulators

Publications (3)

Publication Number Publication Date
JP2011520903A JP2011520903A (ja) 2011-07-21
JP2011520903A5 true JP2011520903A5 (https=) 2012-06-28
JP5603327B2 JP5603327B2 (ja) 2014-10-08

Family

ID=40847864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509679A Active JP5603327B2 (ja) 2008-05-16 2009-05-14 テトラヒドロシクロペンタ[b]インドールアンドロゲン受容体調節物質

Country Status (18)

Country Link
US (1) US8486943B2 (https=)
EP (1) EP2297100B1 (https=)
JP (1) JP5603327B2 (https=)
KR (1) KR101278788B1 (https=)
CN (1) CN102026974B (https=)
AU (1) AU2009246348B2 (https=)
BR (1) BRPI0912394A2 (https=)
CA (1) CA2724629C (https=)
CY (1) CY1113341T1 (https=)
DK (1) DK2297100T3 (https=)
EA (1) EA019713B1 (https=)
ES (1) ES2396612T3 (https=)
HR (1) HRP20120917T1 (https=)
MX (1) MX2010012436A (https=)
PL (1) PL2297100T3 (https=)
PT (1) PT2297100E (https=)
SI (1) SI2297100T1 (https=)
WO (1) WO2009140448A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
ES2488990T3 (es) 2008-02-22 2014-09-01 Radius Health, Inc. Moduladores selectivos del receptor de andrógenos
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
EP2568806B1 (en) 2010-05-12 2016-05-11 Radius Health, Inc. Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
LT3474841T (lt) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ krūties vėžio gydymo būdai
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
KR102707399B1 (ko) 2017-01-05 2024-09-13 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
WO2021151905A1 (en) * 2020-01-27 2021-08-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
US20230255933A1 (en) * 2020-07-06 2023-08-17 Crescenta Biosciences Antiviral use of fabp4 modulating compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
EP2423190A1 (en) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2005092854A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
US8143257B2 (en) 2004-11-23 2012-03-27 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting VEGF production
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
CN101203491A (zh) * 2005-06-24 2008-06-18 伊莱利利公司 可用作雄激素受体调节剂的四氢咔唑衍生物(sarm)
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators

Similar Documents

Publication Publication Date Title
JP2011520903A5 (https=)
HRP20120917T1 (hr) TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA
JP2006182786A5 (https=)
JP2018021051A5 (https=)
JP2012532874A5 (https=)
JP2016534063A5 (https=)
JP2006143751A5 (https=)
JP2010077141A5 (https=)
JP2007535496A5 (https=)
JP2010518122A5 (https=)
JP2013545785A5 (https=)
JP2013518107A5 (https=)
JP2011528713A5 (https=)
GB2465897A (en) Respiratory disease treatment
JP2009533356A5 (https=)
JP2016522254A5 (https=)
JP2015522018A5 (https=)
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
JP2019515908A5 (https=)
JP2008539267A5 (https=)
JP2008539268A5 (https=)
JP2014505107A5 (https=)
JP2013514980A5 (https=)
JP2017501140A5 (https=)
JP2020505354A5 (https=)